Spherix

Skyrizi

Marketing

New IL-23 UC drugs 'rapidly gained significant momentum': report

New drugs are rapidly growing into the established UC market as this IL-23 inhibitor class look to make its mark.

Ben Adams Nov 18, 2024 8:55am

Jardiance

Jardiance poised for challenge to AZ's Farxiga in CKD: Spherix

Jun 27, 2022 5:00am